Association of circulating protein biomarkers with clinical outcomes of durvalumab in head and neck squamous cell carcinoma.

The potential for durvalumab, a programmed cell death ligand-1 (PD-L1)-blocking monoclonal antibody, to treat head and neck squamous cell carcinoma (HNSCC) is being evaluated in multiple clinical t...